Masana'antar harhada magunguna ta kasance masana'antar rufaffiyar ko da yaushe. Masana'antar harhada magunguna koyaushe tana rabuwa da duniyar waje ta hanyar hadaddun ilimin kantin magani da ba a raba su ba. Yanzu wannan bangon yana rushewa saboda fasahar dijital. Ƙari da ƙarin kamfanoni masu hankali na wucin gadi sun fara haɗin gwiwa. tare da masu haɓaka magungunan ƙwayoyi don amfani da fasaha na fasaha na wucin gadi zuwa kowane hanyar haɗin yanar gizo na sabon bincike da ci gaba na miyagun ƙwayoyi da kuma hanzarta sabon bincike na miyagun ƙwayoyi da tsarin ci gaba.
Kwanan nan, AI + sabuwar kasuwar magunguna ta sami labarai mai daɗi akai-akai, kuma kamfanoni da yawa sun kammala babban kuɗi a cikin 2020.
A cikin Yuni 2010, The Drug Discovery A Yau ya buga wani ɗan gajeren bita, "The Upside of Being Digital Pharma Player", wanda yayi nazari akan halin yanzu na aikace-aikacen AI a cikin sassan R & D na 21 Pharmaceutical Giants a duk duniya daga 2014 zuwa 2018. Sakamakon ya nuna cewa FIELD na AI + sababbin magunguna, kodayake har yanzu a farkon matakansa, yana girma.
Bisa kididdigar da aka yi, ya zuwa ranar 16 ga Oktoba, 2020, jimillar sababbin kamfanonin AI+ 56 a cikin gida da waje sun sami kudade, tare da jimlar kudaden da aka tara na dala biliyan 4.581. Daga cikinsu, kamfanoni 37 na kasashen waje sun sami kudade tare da jimlar jimlar. jimlar dalar Amurka 31.65, kuma kamfanoni na cikin gida 19 sun sami tallafi tare da jimillar dalar Amurka biliyan 1.416.
Lokacin aikawa: Nov-03-2020